|
|
|
|
|
|
|
|
|
|
|
Charting a Pathway to Follow-On Biologics
|
|
|
| By
Erik Greb
|
|
|
|
Debates about science, manufacturing, and European regulations will shape the approval process for follow-on biologics in the United States.
|
|
|
|
Drug Serialization and Supply-Chain Security
|
|
|
| By
Alexis Pellek
|
|
|
|
As regulators work to curb counterfeiting, industry finds benefits to gaining granular data about the supply chain. This article contains bonus online-exclusive material.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FDA Waves a Big Stick
|
|
|
| By
Jill Wechsler
|
|
|
|
Agency officials and manufacturers anticipate stricter enforcement of drug safety and quality.
|
|
|
|
|
|
|
|
|
Operator Error
|
|
|
| By
Control, a senior compliance officer
|
|
|
|
Short-term problems in software or hardware lead to long-term manufacturing troubles.
|
|
|
|
|
|
|
|
|
Truth and Transparency
|
|
|
| By
Michelle Hoffman
|
|
|
|
Misleading the public about their investments—be it money or medicine—is unacceptable.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Report From: Ireland
|
|
|
| By
Sean Milmo
|
|
|
|
Despite its shrinking domestic economy, Ireland is determined not to let its pharmaceutical industry fade into the shadow of global recession.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the Spotlight
|
|
|
|
Editors' Picks of Pharmaceutical Science & Technology Innovations
|
|
|
|
|
|
|
|
|
|